AnaptysBio, Inc. (NASDAQ:ANAB) had its target price upped by JMP Securities from $45.00 to $82.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.
A number of other research analysts have also recently commented on the company. Royal Bank Of Canada began coverage on AnaptysBio in a research note on Thursday, September 14th. They set an outperform rating and a $40.00 price objective on the stock. Zacks Investment Research upgraded AnaptysBio from a hold rating to a buy rating and set a $36.00 price objective on the stock in a research note on Wednesday, September 13th. Stifel Nicolaus restated a buy rating and set a $35.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 12th. Credit Suisse Group boosted their price objective on AnaptysBio from $34.00 to $38.00 and gave the stock an outperform rating in a research note on Friday, August 25th. Finally, Robert W. Baird began coverage on AnaptysBio in a research note on Monday, July 10th. They set an outperform rating and a $36.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. AnaptysBio presently has a consensus rating of Buy and a consensus price target of $59.14.
AnaptysBio (ANAB) traded down 3.21% during trading on Tuesday, reaching $68.53. The company had a trading volume of 1,018,301 shares. The firm’s 50 day moving average is $38.75 and its 200-day moving average is $38.75. The company’s market capitalization is $1.39 billion. AnaptysBio has a 12 month low of $15.17 and a 12 month high of $74.00.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. On average, equities analysts expect that AnaptysBio will post ($1.99) earnings per share for the current year.
WARNING: This report was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.truebluetribune.com/2017/10/13/jmp-securities-boosts-anaptysbio-inc-anab-price-target-to-82-00.html.
In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares in the company, valued at $40,862,344.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,133,940 shares of company stock worth $24,223,316.
Several large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new position in shares of AnaptysBio in the first quarter worth about $24,474,000. Artal Group S.A. lifted its stake in shares of AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after acquiring an additional 205,310 shares in the last quarter. Marshall Wace North America L.P. acquired a new position in shares of AnaptysBio in the first quarter worth about $6,924,000. MARSHALL WACE ASIA Ltd acquired a new position in shares of AnaptysBio in the first quarter worth about $6,924,000. Finally, Vanguard Group Inc. lifted its stake in shares of AnaptysBio by 22.6% in the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after acquiring an additional 37,932 shares in the last quarter. Institutional investors and hedge funds own 71.35% of the company’s stock.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.